Abstract:
The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.
Abstract:
Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
Abstract:
The present invention relates to a cell for producing acyl glycinateswherein the cell is genetically modified to comprise -at least a first genetic mutation that increases the expression relative to the wild type cell of an amino acid-N-acyl-transferase, -at least a second genetic mutation that increases the expression relative to the wild type cell of an acyl-CoA synthetase, and -at least a third genetic mutation that decreases the expression relative to the wild type cell of at least one enzyme selected from the group consisting of an enzyme of the glycine cleavage system, glycine hydroxymethyltransferase (GlyA) and threoninealdolase (LtaE).
Abstract:
The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract:
Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
Abstract:
The present invention relates to a cell for producing acyl glycinateswherein the cell is genetically modified to comprise -at least a first genetic mutation that increases the expression relative to the wild type cell of an amino acid-N-acyl-transferase, -at least a second genetic mutation that increases the expression relative to the wild type cell of an acyl-CoA synthetase, and -at least a third genetic mutation that decreases the expression relative to the wild type cell of at least one enzyme selected from the group consisting of an enzyme of the glycine cleavage system, glycine hydroxymethyltransferase (GlyA) and threoninealdolase (LtaE).
Abstract:
The present invention relates to a cell for producing acyl amino acids wherein the cell is genetically modified to comprise - at least a first genetic mutation that increases the expression relative to the wild type cell of an amino acid-N-acyl-transferase, - at least a second genetic mutation that increases the expression relative to the wild type cell of an acyl-CoA synthetase, and - at least a third genetic mutation that decreases the expression relative to the wild type cell of at least one enzyme selected from the group consisting of an enzyme of the glycine cleavage system, glycine hydroxymethyltransferase (GlyA) and threonine aldolase (ItaE).